Preclinical data demonstrate crucial role of Transmembrane Protein 219 (TMEM219) in exacerbating inflammatory bowel disease (IBD) by inducing intestinal epithelial stem cell (ISC) death and impairing mucosal healing Findings support Phase 1 clinical development of Enthera’s lead candidate, Ebrasodebart (Ent001), a monoclonal antibody targeting the IGFBP3/TMEM219 pathway Ebrasodebart is currently being studied in a proof-of-concept […]

Industry veteran Dr. Olson moves from Enthera’s Board to take the helm as CEO Ent001 Phase 1a trial in healthy volunteers completed with positive topline safety results Company has initiated enrollment for Ent001 Phase 1b trial in patients with moderately to severely active ulcerative colitis Milan, Italy, January 23, 2024 – Enthera Pharmaceuticals (“Enthera”), a […]

Milan, Italy, February 16, 2023 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions, today announces the appointment of Filippo Canducci MD, PhD as Chief Medical Officer. Dr. Canducci brings more than 20 years of experience in translational medicine, clinical research and drug development in inflammatory and autoimmune diseases. Prior […]

Milan, Italy, 4 May 2022 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, today announces the appointment of Aled Williams as Chief Executive Officer and member of its Board of Directors. Aled has over twenty-five years of experience as a senior […]

Antonio Speziale joins Enthera with drug development and commercialization experience from roles at Galapagos, Shire, Novartis, Genzyme and Wyeth Milan, Italy, 4 October 2021 – Enthera Pharmaceuticals (“Enthera”), a biotech company developing first-in-class biologics for selected autoimmune conditions based on the discovery of a novel apoptosis pathway, has appointed Antonio Speziale as Chief Medical Officer. […]